Skip to main content

Table 1 Frequencies of people with disturbed levels of anti-melanin and anti-tyrosinase autoantibodies

From: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo

  Healthy control people People with vitiligo Melanoma patients Melanoma patients (without metastases) Melanoma patients (with metastases)
Increased anti-melanin IgM 7 (32) 2 (16) 3 (62) 3 (27) 0 (35)
Decreased anti-melanin IgM 4 (32) 2 (16) 11 (62) 4 (27) 7 (35)
Increased anti-melanin IgA 5 (32) 0 (16) 22 (62) 7 (27) 15 (35)
Decreased anti-melanin IgA 2 (32) 1 (16) 13 (62) 5 (27) 8 (35)
Increased anti-melanin IgG 7 (32) 3 (16) 13 (62) 9 (27) 4 (35)
Decreased anti-melanin IgG 5 (32) 5 (16) 6 (62) 2 (27) 4 (35)
Increased anti-tyrosinase IgM 7 (30) 0 (16) 0 (62) 0 (26) 0 (36)
Decreased anti-tyrosinase IgM 3 (30) 3 (16) 28 (62) 4 (26) 24 (36)
Increased anti-tyrosinase IgA 5 (29) 0 (16) 14 (62) 3 (26) 11 (36)
Decreased anti-tyrosinase IgA 2 (29) 0 (16) 2 (62) 0 (26) 2 (36)
Increased anti-tyrosinase IgG 8 (29) 1 (16) 7 (62) 2 (26) 5 (36)
Decreased anti-tyrosinase IgG 1 (29) 1 (16) 5 (62) 2 (26) 3 (36)